Obaid Hassan Abu, Marques-Vidal Pedro
School of Public Health, Tehran University of Medical Sciences TUMS, Tehran, Iran.
Faculty of Intermediate Studies, Israa University, Gaza, Palestine.
Diabetol Metab Syndr. 2025 Jan 31;17(1):40. doi: 10.1186/s13098-025-01604-z.
In Switzerland, the prevalence of diabetes mellitus (DM) has increased in the general population, but little is known regarding DM-related hospitalizations and their impact on mortality and health costs. Hence, our objectives were to assess (1) the evolution of hospitalizations for DM as first diagnosis and as comorbidity; (2) the association of DM with ICU admission, length of stay (LOS), in-hospital mortality and costs.
Swiss hospital discharge data for period 2012-2020. Type 1 (T1DM), type 2 (T2DM) and other types (OTDM) of DM were considered.
Between 2012 and 2020, the number of hospitalizations (% total) increased from 4204 (0.27) to 4980 (0.45) for T2DM, 539 (0.05) to 854 (0.08) for T1DM and 221 (0.02) to 381 (0.03) or OTDM. Hospitalizations with DM as comorbidity increased from 89,752 (8.6) to 128,700 (11.7) for T2DM, 2934 (0.29) to 3536 (0.32) or T1DM and 5774 (0.58) to 9143 (0.83) for OTDM. Compared to non-DM hospitalizations, all types of DM had a higher likelihood of lower limb amputation; hospitalizations for T1DM had a higher likelihood of ICU admission: odds ratio and 95% CI: 3.38 (3.19-3.59), while T2DM had higher LOS: 5.5 ± 1.0 vs. 5.1 ± 1.0 days, and all DM types had a lower odds of in-hospital mortality. Patients with any type of DM as comorbidity had a longer LOS than patients without. Total cost of DM rose from CHF 42 million in 2012 to almost 100 million in 2019 and decreased afterwards.
DM represents an increasing health and economic burden in Switzerland.
在瑞士,普通人群中糖尿病(DM)的患病率有所上升,但关于糖尿病相关住院情况及其对死亡率和医疗成本的影响知之甚少。因此,我们的目标是评估:(1)作为首次诊断和合并症的糖尿病住院情况的演变;(2)糖尿病与重症监护病房(ICU)入住、住院时间(LOS)、院内死亡率和成本之间的关联。
采用2012 - 2020年瑞士医院出院数据。考虑了1型糖尿病(T1DM)、2型糖尿病(T2DM)和其他类型糖尿病(OTDM)。
2012年至2020年期间,T2DM作为首次诊断的住院人数(占总住院人数的百分比)从4204例(0.27%)增至4980例(0.45%),T1DM从539例(0.05%)增至854例(0.08%),OTDM从221例(0.02%)增至381例(0.03%)。T2DM作为合并症的住院人数从89752例(8.6%)增至128700例(11.7%),T1DM从2934例(0.29%)增至3536例(0.32%),OTDM从5774例(0.58%)增至9143例(0.83%)。与非糖尿病住院患者相比,所有类型的糖尿病患者下肢截肢的可能性更高;T1DM住院患者入住ICU的可能性更高:优势比及95%置信区间为3.38(3.19 - 3.59),而T2DM的住院时间更长:5.5±1.0天对5.1±1.0天,所有类型糖尿病患者院内死亡的几率更低。患有任何类型糖尿病合并症的患者住院时间比未患合并症的患者更长。糖尿病的总成本从2012年的4200万瑞士法郎增至2019年的近1亿瑞士法郎,随后有所下降。
在瑞士,糖尿病带来的健康和经济负担日益加重。